Eric Sherb was named Chief Financial Officer of Apimeds Pharmaceuticals US, Inc., succeeding Erick Frim, effective October 1, 2026. As of November 6, 2026, Apimeds Pharmaceuticals US, Inc. has reported 4 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 9, 2026 to October 1, 2026, naming 3 appointments and 1 departure (Form 8-K, October 1, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Apimeds Pharmaceuticals US, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Out · Person: Erick Frim · Role: Chief Financial Officer · 8-K, 2026-10-01
- · In / out: In · Person: Sungjoon Chae · Role: Chief Executive Officer · 8-K, 2026-05-05
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-05-04
- · In / out: Reported · Person: not named in the filing · 8-K/A, 2026-04-09
Apimeds Pharmaceuticals US, Inc. reported changes in 4 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-09 to 2026-10-01. They name 3 people, with 3 appointments and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Apimeds Pharmaceuticals US, Inc. files it.
Also on the record for Apimeds Pharmaceuticals US, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 7, 2026 | Stake report, Schedule 13D/A, by Inscobee Inc. | 34.3% of the class | 5%+ stakes | Source |
| March 30, 2026 | Stake report, Schedule 13D/A, by Inscobee Inc. | 34.3% of the class | 5%+ stakes | Source |
| March 20, 2026 | Stake report, Schedule 13D/A, by Inscobee Inc. | 34.3% of the class | 5%+ stakes | Source |
| February 11, 2026 | Stake report, Schedule 13G, by Ayrton Capital LLC | 9.99% of the class | 5%+ stakes | Source |
| January 26, 2026 | Stake report, Schedule 13D/A, by Inscobee Inc. | 34.3% of the class | 5%+ stakes | Source |
| May 9, 2025 | IPO filing, Form 424B4 | — | IPO filings | Source |
| February 10, 2025 | IPO filing, Form S-1/A | — | IPO filings | Source |
| February 6, 2025 | IPO filing, Form S-1/A | — | IPO filings | Source |
| January 29, 2025 | IPO filing, Form S-1/A | — | IPO filings | Source |
| January 10, 2025 | IPO filing, Form S-1/A | — | IPO filings | Source |
| December 20, 2024 | IPO filing, Form S-1/A | — | IPO filings | Source |
| December 9, 2024 | IPO filing, Form S-1/A | — | IPO filings | Source |
Selling to them or working with them? See who runs Apimeds Pharmaceuticals US, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Apimeds Pharmaceuticals US, Inc. and the records around it.
Apimeds Pharmaceuticals US, Inc. elsewhere on the record
- 5%+ stake filings May 2026
- IPO filing May 2025
- Who owns it
Companies that share a holder
- Ayrton Capital LLC also filed stake reports on 31 other companies: Bluejay Diagnostics, Inc. (Aug 2026), BTC Digital Ltd. (Aug 2026), DEFSEC Technologies Inc. (Aug 2026)
Watch Apimeds Pharmaceuticals US, Inc.
Get an email when Apimeds Pharmaceuticals US, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Apimeds Pharmaceuticals US, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Apimeds Pharmaceuticals US, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Apimeds Pharmaceuticals US, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 14 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-01 | Out | Chief Financial Officer | 8-K, 2026-10-01 | ||
| 2026-10-01 | In | Chief Financial Officer | 2026-10-01 | 8-K, 2026-10-01 | |
| 2026-10-01 | In | 8-K, 2026-10-01 | |||
| 2026-05-05 | In | Chief Executive Officer | 8-K, 2026-05-05 | ||
| 2026-05-04 | Reported | not named in the filing | 8-K, 2026-05-04 | ||
| 2026-04-09 | Reported | not named in the filing | 8-K/A, 2026-04-09 |
Who leads Apimeds Pharmaceuticals US, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Erick Frim, departure reported (filed 2026-10-01). No successor is named in these filings.
- Chief Executive Officer: Sungjoon Chae, appointed (filed 2026-05-05).
New leaders reset buying decisions — get the Full Report on Apimeds Pharmaceuticals US, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Apimeds Pharmaceuticals US, Inc., with the record behind each one.
Find candidates like Chief Financial Officer at Apimeds Pharmaceuticals US, Inc.Every change, in the filing's words
Departing: Erick Frim, Chief Financial Officer
On September 29, 2026, Erick Frim notified Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the " Company "), of his resignation as Interim Chief Financial Officer of the Company, effective immediately.
Appointed: Eric Sherb, Chief Financial Officer, effective 2026-10-01
On September 30, 2026, the Board of Directors (the " Board ") of the Company appointed Eric Sherb, age 40, as Chief Financial Officer of the Company, effective October 1, 2026.
Appointed: Eric Sherb
Mr. Sherb will serve as the Company's principal financial officer and principal accounting officer.
- As previously disclosed, Mr. Frim was reappointed as Interim Chief Financial Officer on March 30, 2026.
- Mr. Frim's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
- Mr. Sherb is a Certified Public Accountant with over 18 years of experience in the capital markets.
- In January 2019, Mr. Sherb founded EMS Consulting Services, LLC, an accounting and advisory firm, where he has since served as its Principal.
- Through EMS Consulting Services, Mr. Sherb has assisted private and public companies via CFO services, complex technical accounting, U.S. GAAP and SEC reporting, PCAOB audit coordination, IPO readiness, mergers and acquisitions, corporate governance, and the oversight of accounting and controllership functions.
- Prior to founding EMS Consulting Services, Mr. Sherb began his career at PricewaterhouseCoopers LLP in New York before working at mid-market accounting and advisory firms in the capital markets.
- Mr. Sherb received his degree from Emory University.
- Since February 2026, through EMS Consulting Services, Mr. Sherb has also served as fractional Chief Financial Officer of MindWave Innovations Inc., a wholly owned subsidiary of the Company, an engagement that will terminate in connection with his appointment.
Appointed: Sungjoon Chae, Chief Executive Officer
On May 4, 2026, pursuant to a nomination by a stockholder of Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the " Company "), the board of directors of the Company (the " Board ") appointed Sungjoon Chae to serve as Co-Chief Executive Officer of the Company, effective as of such date.
- Biographical information for Sungjoon Chae is set forth below: Sungjoon Chae is an architect and urban designer specializing in large-scale real estate development and urban regeneration.
- In 2013, he obtained Master of Architecture in Urban Design from Harvard University and has extensive experience in planning and delivering complex, mixed-use and urban-scale projects across South Korea and the United States.
- His work focuses on the integration of architecture, urban planning, and real estate strategy, with particular expertise in urban revitalization, site planning, and development-driven design.
- He has been involved in projects requiring coordination across multiple stakeholders, including developers, investors, public agencies, and design teams, and has contributed to projects from early-stage planning and feasibility through design development and execution.
- Mr. Chae brings a practical, implementation-oriented approach to real estate and urban development, aligning design intent with financial viability, regulatory frameworks, and market conditions.
Reported
Under the Settlement Agreement, the Inscobee Parties have agreed to secure the resignation or removal of Mr. Koo.
- As previously disclosed, on December 30, 2025 and March 20, 2026, certain stockholders of the Company, including the Inscobee Parties, purported to execute written consents of stockholders (the "Stockholder Consents") to, among other things, remove Elona Kogan, Jakap Koo, Carol O'Donnell, and Dr. Bennett Weintraub from the Company's board of directors and appoint replacement directors.
- In connection with the Settlement Agreement, the parties have agreed that the Support Agreements and Voting Agreements previously entered into by the Inscobee Parties in connection with the Merger Agreement are valid and binding, that the Stockholder Consents are void, and that all actions taken pursuant to the Stockholder Consents, including the purported removal of directors and any actions taken by the purported replacement board, are void.
- Accordingly, the Company's board of directors continues to consist of Elona Kogan, Jakap Koo, Carol O'Donnell, and Dr. Bennett Weintraub.
- Following Mr. Koo's resignation or removal, and during the period between the effective date of the Settlement Agreement and the filing of the Company's Annual Report on Form 10-K (the "Interim Period"), the Company's board will consist solely of Ms. Kogan, Ms. O'Donnell and Dr. Weintraub.
Reported
The Stockholder Consent, including the Board Removals, the Officer Removals, and the purported appointment of replacement directors, is null and void, having been taken in direct violation of binding contractual obligations under the Support Agreement (as defined below) and applicable Delaware law.
- As previously announced, the Company entered into that certain Agreement and Plan of Merger, signed and closed on December 1, 2025 (the "Merger Agreement"), with Apimeds Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company, MindWave Innovations Inc., a Delaware corporation ("MindWave"), and other parties signatory thereto.
- Pursuant to the Merger Agreement, MindWave became a wholly owned subsidiary of the Company by virtue of a merger (the "Merger").
- In connection with the Merger, Inscobee and Apimeds Korea each entered into a Stockholder Support and Lock-Up Agreement (the "Support Agreement") with the Company and MindWave.
- The Stockholder Consent violated at least three independent provisions of the Support Agreement: Irrevocable Proxy (Section 4(a)(4)).
- Under the Support Agreement, Inscobee and Apimeds Korea each unconditionally and irrevocably granted to the Company a proxy and power of attorney to vote their shares of common stock in a manner consistent with the Support Agreement.
- The Support Agreement expressly provides that this irrevocable proxy is "coupled with an interest" and "may under no circumstances be revoked." The Stockholder Consent used 6,416,365 shares of common stock that were subject to this irrevocable proxy.
- The Company, as proxy holder, did not authorize the use of these shares for the Stockholder Consent.
Tools for this story
Each opens in a new tab, filled in for Apimeds Pharmaceuticals US, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.